Novacyt S.A. AGM Voting (3572Z)

TIDMNCYT

RNS Number : 3572Z

Novacyt S.A.

18 September 2020

Novacyt S.A.

( " Novacyt " , the " Company " or the "Group")

AGM voting

Paris, France and Camberley, UK - 18 September 2020 - Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as a closed meeting at 2pm CEST/1pm BST on 29 September 2020. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

Due to precautionary measures put in place by the French Government as a result of the COVID-19 pandemic, and with the health and safety of its shareholders and employees being a priority, the AGM will be held without the physical presence of shareholders.

Under French law, for the meetings to be quorate at the first attempt, at least 20% of the shareholders must vote on the ordinary resolutions and 25% of the shareholders must vote on the extraordinary resolutions. Shareholders are therefore strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the notice convening the meeting, copies of which are available in the General Meetings section on the Company's website at www.novacyt.com .

Following registration via the Company's website, shareholders will be able to view a live webcast of the AGM which will include a presentation made by Graham Mullis, Chief Executive Officer of the Group. Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com .

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] ; [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

[phone]

[e-mail] / [e-mail]

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAKKOBBABKDDCD

(END) Dow Jones Newswires

September 18, 2020 02:00 ET (06:00 GMT)